Multiple Sclerosis Pathway - Provider Information: MS Drugs
There is strong evidence that disease-modifying therapy (DMT) for MS reduces the number and severity of relapses and slows the worsening of disability, particularly if initiated early in the course of the disease. However, treatment is not indicated for all patients or all disease stages. A neurologist may initiate discussions about pharmacological therapy with patient and family quite soon after making a diagnosis. There is considerable variety in DMTs available. Patient readiness for DMT and preferences in terms of route of administration, lifestyle, efficacy, common adverse effects, and tolerability should be considered, and may improve acceptance of and adherence to therapy.
Primary care providers play a role in addressing side effects and co-morbid conditions, such as depression, and monitoring for medication adherence, tolerability, safety, and effectiveness of the therapy. A concise repository of information is available at MS Protocols.
A nurse educator is provided by the Saskatchewan MS Drugs Program to assist the patient and family to consider the requirements, risks, and benefits of various treatments. The MS Nurse Educator is located at the MS Clinic Saskatoon but is available by phone to all residents toll free at 1-866-655-7966. Inquiries are welcome from both patients and providers.
In Saskatchewan, disease-modifying therapies are reviewed and approved by the MS Drugs Advisory Panel for the MS Drugs Program, and are eligible for Exception Drug Status. Coverage requires the prescribing physician to submit an application to the MS Drugs Program for approval, followed by an annual application for Exception Drug Status to the Saskatchewan Drug Plan.